drugset / Trial / NCT06355037
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.
Timeline
- Start
- 2024-05-20
- Primary completion
- 2024-12-31
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quercetin | Small molecule | 1000 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 50 mg | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Eribulin | Small molecule | — | — |
| Background | UTD1 | Unknown | — | — |
| Background | Vinorelbine | Small molecule | — | — |